

Article

Ferroptosis Suppressor Protein 1 (FSP1)-CoQ10-NADPH-Axis Is Responsible for Erastin Resistance in MCF-7 Breast Cancer Cells

Brian B. Silver, Carri Murphy, Erik J. Tokar  and Birandra K. Sinha *

Mechanistic Toxicology Branch, Division of Translational Toxicology, National Institute of Environmental Health, National Institutes of Health, Research Triangle Park, Durham, NC 27709, USA; brian.silver@nih.gov (B.B.S.); carri.murphy@nih.gov (C.M.); erik.tokar@nih.gov (E.J.T.)

* Correspondence: sinha1@niehs.nih.gov

Abstract

Ferroptosis has emerged as a promising therapeutic strategy for drug-resistant cancers; however, the molecular mechanisms governing ferroptosis susceptibility in breast cancer remain poorly defined. Here, we have investigated distinct ferroptosis resistance mechanisms in parental MCF-7 breast cancer cells and their BCRP-overexpressing derivative, MCF-7/MXR. MCF-7/MXR cells displayed robust erastin (ER)-induced ferroptosis characterized by extensive lipid peroxidation, ROS accumulation, and suppression of the xCT-GSH-GPX4 axis. In contrast, MCF-7 cells were resistant to ER, exhibiting minimal lipid damage despite measurable ER-induced oxidative stress. We found that this resistance is mediated not by the canonical GPX4 pathway, but by a potent compensatory antioxidant system centered on the FSP1-CoQ10-NADPH axis. Pharmacological inhibition of FSP1 strongly sensitized MCF-7 cells to ER, with minimal effects in MXR cells. ER differentially regulated ferroptosis-associated genes, downregulating GPX4, and SLC7A11 in MXR cells but upregulating the GPX4 pathway in MCF-7 cells. Additionally, ER downregulated FSP1 and NQO1 in MCF-7 cells without affecting their expressions in MXR cells. This mechanistic divergence highlights that ferroptosis resistance in breast cancer is context-dependent and mediated by pathway-specific antioxidant programs. Co-targeting FSP1 and GPX4 therefore represents a rational strategy to overcome ferroptosis resistance in MCF-7-like breast cancers.

Keywords: ferroptosis; resistance; breast cancer; erastin; FSP1; CoQ10; NQO1



Academic Editors: Hugo Pequeno Monteiro and Jordi Oliver

Received: 29 December 2025

Revised: 22 January 2026

Accepted: 7 February 2026

Published: 11 February 2026

Copyright: © 2026 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the [Creative Commons Attribution \(CC BY\)](https://creativecommons.org/licenses/by/4.0/) license.

1. Introduction

Breast cancer is a serious global threat to women's health, and emergence of multidrug resistance following chemotherapy leads to poor prognosis and decreased survival rates [1–3]. Erastin (ER) and its analogs are promising anticancer agents due to their ability to sensitize resistant tumor cells to chemotherapeutic agents [4]. It has been found that triggering ferroptosis in breast cancer cells can significantly inhibit their proliferation and invasion, as well as improving sensitivity to radiotherapy and chemotherapy [4]. Accordingly, drugs that induce ferroptotic tumor cell death have attracted attention as a potential therapeutic strategy, particularly for cancers refractory to conventional therapies [5].

Ferroptosis plays a critical role in cancer and chemical toxicology due to its unique cell death mechanism that is driven by iron-dependent lipid peroxidation [6–9]. Ferroptotic cell death has been shown to be morphologically, biochemically, and genetically distinct from other forms of cell death such as apoptosis, necrosis, and autophagy [6,8,10]. Ferroptosis is

characterized by the accumulation of lethal reactive oxygen species (ROSs) and lipid radicals, resulting in damage to cellular membranes and causing ferroptosis [6,8,10]. Human normal as well as tumor cells have an enhanced antioxidant system and protect cells from this ROS-induced toxicity. This system includes superoxide dismutase (SOD), catalase (CAT), glutathione peroxidases (GPXs), and reduced glutathione to protect cells [11]. This mechanism has become extremely relevant to cancer treatment and cancer-related diseases because exposure to certain anticancer drugs can intensify oxidative stress, leading to ferroptotic cell death [9] as well as damage in organs like the liver, kidneys, and lungs [12].

At the molecular level, ER induces ferroptosis by suppressing the glutamate/cystine antiporter (system xCT), leading to inhibition of cellular cystine uptake and inhibiting glutathione synthesis [13]. System xCT, composed of the light-chain SLC7A11 and the heavy-chain SLC3A2, has been reported to be a key regulator of cellular redox homeostasis. It mediates the uptake of extracellular cystine in exchange for intracellular glutamate, supplying cystine for its intracellular reduction to cysteine, the rate-limiting precursor for glutathione (GSH) synthesis. By maintaining GSH levels, system xCT supports the activity of antioxidant enzymes such as GPX4 and thereby protects cells from lipid peroxidation and oxidative stress. Inhibition of system xCT causes a rapid drop in intracellular glutathione levels, resulting in cell death from the accumulation of lipid-derived reactive oxygen species (ROSs). Glutathione is a primary cellular antioxidant that plays critical roles in maintaining the redox balance and defending against oxidative stress, including ROS. Not only ER has been shown to induce ferroptosis in several types of cancer cells, and it is selectively more cytotoxic to tumors harboring RAS mutations [14]. During ferroptosis, glutathione peroxidase 4 (GPX4) is inhibited, and intracellular lipid hydroperoxides (LOOHs) accumulate, causing damage to cellular membranes (lipid peroxidation) in the presence of iron [15].

Ferroptosis suppressor protein 1 (FSP1; also called AIFM2 or AMID) utilizes NAD(P)H to reduce oxidized coenzyme Q10 (ubiquinone) to its active, reduced form, ubiquinol. Ubiquinol (CoQH₂) then acts as an antioxidant that neutralizes lipid radicals, preventing them from propagating and initiating ferroptosis [16,17]. FSP1 can also reduce vitamin K to its hydroquinone form (VKH) to inhibit ferroptosis. Ferroptosis inducers (FIN) inactivate these ferroptosis surveillance systems, leading to a rapid buildup of lipid peroxides, causing ferroptosis in many cancer cell lines and in vivo tumor models [6,10].

Recently, we as well as others have shown that ER is extremely effective in reversing and sensitizing various chemotherapeutic agents in several ABC transporter-expressing cell lines. We found that ER effectively reverses resistance to Adriamycin and topotecan in ABCB1- and ABCG2-expressing tumor cell lines by enhancing cellular uptake of Adriamycin and topotecan, respectively [18–20]. More importantly, our studies showed that both ER and RSL3 (Ras selective ligand3) were significantly more cytotoxic to MCF-7/MXR cells, a BCRP-expressing cell line [20], than the parent MCF-7 cells. Furthermore, both ER and RSL3 were effective in reversing topotecan resistance in the MCF-7/MXR breast cancer cell line [20].

Our previous studies demonstrating ER enhanced cytotoxicity of topotecan in MCF-7/MXR breast cancer cells suggested that ferroptosis inducers may be clinically valuable in combination with existing chemotherapeutics for the treatment of resistant breast cancers [20]. However, the mechanisms of ER-induced cell death and resistance in breast cancer cells are poorly understood. Understanding the mechanisms and pathways of how cancer cells acquire resistance to ferroptosis are extremely important for the development of newer strategies to specifically target breast cancer cells.

In this study, we investigated mechanisms underlying the differential sensitivity of parental MCF-7 breast cancer cells and their BCRP-overexpressing derivative, MCF-7/MXR, to ferroptosis-inducing agents, with a particular focus on ER. Our findings indicate that an enhanced antioxidant system centered on the FSP1–CoQ10–NADPH axis plays a key role in me-

diating ER resistance in MCF-7 cells, whereas reduced GSH levels together with ER-dependent inhibition of GPX4 activity enhances ER sensitivity to MCF-7/MXR cells. Ultimately, this knowledge could aid the development of highly effective ferroptosis-based treatments towards advancing cancer therapies.

2. Materials and Methods

Erastin, RSL3, Ferrostatin-1, DFO, N-acetyl cysteine (NAC), FSEN1 and iFSP1 were purchased from Cayman Chemicals (Ann Arbor, MI, USA) and were dissolved in DMSO. Stock solutions were stored at -80°C . Fresh drug solutions, prepared from the stock solutions, were used in all experiments.

2.1. Cell Culture

Human MCF-7 breast tumor cells were purchased from ATCC (Manassas, VA, USA). MCF-7/MXR breast tumor cells (MXR) were a gift from Dr. Erasmus Schneider (NCI/NIH [21]). Cells were cultured in Phenol Red-free RPMI media supplemented with 10% fetal bovine serum and antibiotics. Cells were only used for 20–25 passages, after which a new cell culture was started from fresh, frozen stock.

2.2. Cytotoxicity Studies

For cytotoxicity studies, both CellTiter-Glo (Promega, Madison, WI, USA) and Trypan Exclusion methods were utilized. We seeded about 2500–3000 cells/well for CellTiter-Glo assay in opaque white, 96-well plates that were allowed to attach overnight. Cells were then treated with various concentrations of drugs for 72 h, and cytotoxicity was determined according to the manufacturer's instructions. For the Trypan Blue assay, about 30,000–40,000 cells/well were seeded onto a 12-well plate, and were allowed to attach for 24 h and treated with various drugs for 24 h. Following trypsinization, surviving cells were collected and 15 μL of cell mixtures were combined with 15 μL of Trypan Blue and counted in T20 automatic cell counter (Bio-Rad, Hercules, CA, USA). Effects of various inhibitors (DFO, NAC, FES, FESN1, and iFSP1) were examined on the cytotoxicity of ER by preincubating with inhibitors for 1–2 h followed by the addition of various concentrations of ER and incubated for 24 h in complete medium.

2.3. Lipid Peroxidation Assay

Formation of malondialdehyde (MDA) using 2-thiobarbituric acid was used to assess cellular lipid peroxidation as previously described [22]. Briefly, approximately $2.5\text{--}3.0 \times 10^6$ cells/mL (2 mL) were incubated with different concentrations of ER for 4 h at 37°C . The reactions were terminated by adding 2 mL of 10% trichloroacetic acid, followed by centrifugation at $1000 \times g$ for 5 min. Aliquots (1.5 mL) of the supernatants were mixed with 1.5 mL of 2% 2-thiobarbituric acid, and the mixture was heated to 90°C for 10 min to develop the chromophore. After cooling, absorbance was measured at 532 nm.

2.4. RT-PCR

The expression levels of selected transcripts were confirmed by reverse transcription polymerase chain reaction (RT-PCR) using Absolute SYBR Green ROX Mix (Thermo Fisher Scientific, Rochester, NY, USA) as previously described [23]. Relative gene expression was analyzed using the $\Delta\Delta\text{Ct}$ method, with cycle threshold values normalized to β -actin in time-matched samples. Primers for the selected genes were obtained from OriGene (Gaithersburg, MD; Table 1). Real-time fluorescence detection was performed using an iCycler system (Bio-Rad, Hercules, CA). Data are presented as mean $\pm$ SEM from three independent experiments and were analyzed using an unpaired Student's *t*-test, with $p \leq 0.05$ considered statistically significant.

Table 1. Primers used and their sequences.

Gene	Forward	Reverse
Beta-Actin	CACCATTGGCAATGAGCGGTTC	AGGTCTTTGCGGATGTCCACGT
GPX4	ACAAGAACGGCTGCGTGGTGAA	GCCACACACTTGTGGAGCTAGA
CHAC1	GTGGTGACGCTCCTTGAAGATC	GAAGGTGACCTCCTTGGTATCG
HMOX1	CCAGGCAGAGAATGCTGAGTTC	AAGACTGGGCTCTCCTTGTTC
SLC7A11	TCCTGCTTTGGCTCCATGAACG	AGAGGAGTGTGCTTGC GGACAT
FSP1	GACTCCTCCACCACAATGTGG	CAGCACCATCTGGTTCTTCAGG
NQO1	CCTGCCATTCTGAAAGGCTGGT	GTGGTGATGGAAGCACTGCCT
NrF2	CACATCCAGTCAGAAACCAGTGG	GGAATGTCTGCGCCAAAAGCTG
GSR	TATGTGAGCCGCTGAATGCCA	CACTGACCTCTATTGTGGGCTTG
SOD1	CTCACTCTCAGGAGACCATTGC	CCACAAGCCAAACGACTTCCAG
SOD2	CTGGACAAACCTCAGCCCTAAC	AACCTGAGCCTTGGACACCAAC

2.5. Detection of ROS

Invitrogen Molecular Probes fluorogenic reagents—CellROX Deep Red—was utilized for the detection and quantitation of ROS in MCF-7 and MCF-7/MXR cells following treatment with ER. The CellRox reagent is cell-permeable and is nonfluorescent in the reduced state. Upon oxidation by ROS, the reagents exhibit a strong fluorogenic signal that has an absorption/emission maxima of 644/665 nm and remains localized in the cytoplasm [24,25]. Cells were incubated with different concentrations of ER for 2–4 h in RPMI 1640 (no phenol red RPMI1640 media supplemented with 2.0% FBS) media. Following treatment, media was removed and washed twice with media followed by ice-cold PBS (4 x). Cells were then placed on ice in 1 mL PBS and fluorescence was imaged on a Zeiss inverted epifluorescent microscope.

Statistical Analysis: The results are expressed as mean $\pm$ SEM of minimum of 3 independent experiments ($n = 3$). One-way analysis of variance (ANOVA) or Student's *t*-test was used for statistical analysis using Graph Pad Prism (GraphPad Software, Inc., La Jolla, CA, USA) and the results were considered statistically significant when $p < 0.05$.

3. Results

3.1. Cytotoxicity of ER and RSL3 in MCF-7 and MXR Cells

As previously reported, ER and RSL3 were significantly cytotoxic to MCF-7/MXR cells compared to parent MCF-7 cells (Figure 1) at 24 h and 72 h. MCF-7 cells were almost 10-fold resistant to both ER (Figure 1A–C) and RSL3 (Figure 1D,E).




Figure 1. Cytotoxicity of ER as determined by CellTiter-Glo assay following 72 h exposure (A) and Trypan Blue assay at 24 h treatment (B,C) and cytotoxicity of RSL3 after 24 h treatment (D,E). *, ** and *** p values < 0.05 , 0.005 and 0.001 , respectively compared to untreated control. Student's *t*-test was used for statistical analysis using Graph Pad Prism (GraphPad Software, Inc., La Jolla, CA, USA).

3.2. RSL3 Enhances ER Cytotoxicity in MCF-7 and MXR Cells

RSL3, a direct inhibitor of GPX4, significantly enhanced cytotoxicity of ER in both cell lines (Figure 2A,B), suggesting that GPX4 was involved in the cytotoxicity of ER in these cells. This increased ER cytotoxicity was significantly attenuated by NAC (Figure 2C,D), indicating ROS-mediated cytotoxicity.




Figure 2. Enhancement of erastin cytotoxicity by RSL3 in MCF-7 (A) and MXR (B) breast cancer cells and effects of NAC on RSL3-dependent cytotoxicity in MCF-7 (C) and MXR (D) cells. *, ** and *** p values < 0.05, 0.005 and 0.001, respectively compared to untreated control. #, ## p values < 0.05, and 0.005, respectively compared to ER treated alone. ##, and ### p values < 0.005 and 0.001, respectively compared to NAC treated vs. RSL3 treated alone. Student's t -test was used for statistical analysis using Graph Pad Prism (GraphPad Software, Inc., La Jolla, CA, USA).

3.3. Ferrostatin-1, DFO and NAC Decrease Erastin Cytotoxicity in MCF-7 and MXR Cells

Ferrostatin-1 (FES) and DFO, an iron chelator, are known inhibitors of ferroptosis. NAC is a known inhibitor of ROS. We utilized these agents to evaluate ER cytotoxicity in MCF-7 and MXR cells. As shown in Figure 3, these agents (at minimally cytotoxic doses) were highly effective in inhibiting ER cytotoxicity in MCF-7 and MXR cells, suggesting that ER cytotoxicity is ROS driven, is dependent upon presence of iron and formation of the lipid peroxides, which is a key factor in ferroptotic cell death.




Figure 3. Effects of FES (2.0 μ M), DFO (50 μ M) and NAC (50 μ M) on the cytotoxicity of ER in MCF-7 (A,C,E) and MXR (B,D,F) cells. *, ** and *** p values < 0.05, 0.005 and 0.001, respectively compared to untreated control. #, ##, and ### p values < 0.5, <0.005 and 0.001, respectively compared to ER treated alone. Student's t -test was used for statistical analysis using Graph Pad Prism (GraphPad Software, Inc., La Jolla, CA, USA).

3.4. ER Induces Lipid Peroxidation in MXR Cells

Formation of lipid peroxides by ER in MCF-7 and MXR cells was investigated. As shown in Figure 4A, significant amounts of peroxidation (measured as MDA) were detected only in MXR cells in a dose-dependent manner. In contrast, no MDA formation was detected in MCF-7 cells (Figure 4A). The effect of RSL3 on MDA formation was also examined since GPX4 is a known quencher of peroxide formation. As shown in Figure 4B, RSL3 significantly induced MDA formation in MCF-7 cells without markedly affecting MDA formation in MXR cells. However, more MDA was formed in MXR cells than MCF-7 cells when treated with RSL3.




Figure 4. Formation of lipid peroxides, measured as MDA (OD at 532) following treatment of MCF-7 and MXR cells with erastin for 4 h (A) and in the presence of RSL3 (1.0 μ M, (B)) in MCF-7 cells. ** and *** p values < 0.005 and 0.001, respectively compared to untreated control. # p value < 0.05 compared to ER, 5 μ M + RSL3 treated samples. Student's t -test was used for statistical analysis using Graph Pad Prism (GraphPad Software, Inc., La Jolla, CA, USA).

3.5. Erastin Forms ROS in MCF-7 and MXR Cells

ER is known to generate ROS, causing oxidative damage in cells and leading to cell death [24,25]. Formation of ROS was therefore examined in MCF-7 and MXR cells using CellRox Deep Red [26,27], producing brightly deep red fluorescent. As shown in Figure 5, ER generated significant amounts of ROS in both cells in a dose-dependent manner. However, significantly more ROS was formed in MXR cells compared to MCF-7 cells, especially at lower concentrations of ER (Figure 5, ER at 5 μ M and 10 μ M).

3.6. Modulations of Gene Expression Changes by ER in MCF-7 and MXR Cells

RT-PCR studies were carried out to monitor changes in gene expressions by ER. As shown in Figure 6, ER significantly modulated activity of several oxidative stress- and ferroptosis-related genes. Heme oxygenase-1 gene (*HMOX1*) expression was significantly induced in both cells by ER, indicating an enhanced labile iron pool and oxidative stress in both cells. *CHAC1*, responsible for hydrolysis (degradation) of cellular GSH, was markedly increased in MCF-7 cells while ER decreased *CHAC1* expression in MXR cells. Although ER treatment significantly inhibited *GPX4* expression in MXR cells, it was induced in MCF-7 cells. *SLC7A11*, the Xc- transporter, was induced in MCF-7 by ER, but was significantly inhibited in MXR cells.




Figure 5. Formation of ROS from ER in MCF-7 and MXR cells. CellROX, utilized to detect ROS, produced fluorescent red as shown, confirming formation of ROS.




Figure 6. Effects of ER (5.0µM) in MCF-7 and ER (1.0µM) MXR cells following 24 h ER treatment on ferroptosis-related genes (A), FSP1, NQO1 and antioxidant genes (B) and the basal levels of FSP1, GPX4, SLC7A11 and NQO1 in MCF-7 and MXR cells (C). *, ** and *** *p* values < 0.05, 0.005 and 0.001, respectively compared to untreated control. Student's *t*-test was used for statistical analysis using Graph Pad Prism (GraphPad Software, Inc., La Jolla, CA, USA). The ns means not significant.

3.7. Effects of Inhibitors of FSP1 on Erastin Cytotoxicity in MCF-7 and MXR Cells

To elucidate mechanism of differential cytotoxicity of ER in these cells, effects of various known inhibitors of FSP1, a protein involved in the inhibition of ferroptosis in cells and causing drug resistance [28–31], was examined. Treatment of MCF-7 and MXR with FSEN1, a strong non-competitive inhibitor of substrate-binding pocket of FSP1 [32,33], showed similar cytotoxicity in both cell lines. Treatment of MCF-7 and MXR cells with a non-toxic dose of FSEN1 in the presence of ER showed markedly

different outcomes; FSEN1 significantly enhanced ER cytotoxicity in MCF-7 while it had minimal effects on ER cytotoxicity in MXR cells (Figure 7). These observations suggest that MCF-7 cells have either higher expression of FSP1 or are dependent upon the FSP1/CoQ10 pathway for their antioxidant defense, based on their decreased sensitivity to ER-induced ferroptosis as observed here. In contrast, MXR cells must have lower expression of FSP1 or other antioxidants as FSEN1 does not affect the cytotoxicity of ER on MXR cells.

To further confirm these observations, we utilized another inhibitor of FSP1. iFSP1 is a known inhibitor of FSP1 but differs from FSEN1 in that it binds to the FSP1 protein and deactivates its oxidoreductase function, preventing FSP1 from using NAD(P)H to reduce ubiquinone [16]. iFSP1 was not significantly toxic to MCF-7 cells at concentrations utilized here (Figure 7E), but was cytotoxic to MXR cells at higher concentrations (Figure 7F). iFSP1, when used at minimally cytotoxic doses (10 μ M), significantly enhanced cytotoxicity of ER in MCF-7 cells (Figure 7G), but it had minimal effects on ER cytotoxicity in MXR cells (Figure 7H). These results further suggest that MCF-7 cells depend upon the FSP1-coenzyme Q10 (CoQ10)-NAD(P)H axis for its antioxidant properties to prevent ferroptosis and reduce cytotoxicity of ER in MCF-7 cells.




Figure 7. Effects of FSEN1 $\pm$ ER in MCF-7 (A,B) and MXR cells (C,D) and iFSP1 $\pm$ ER in MCF-7 (E,F) and MXR (G,H) cells following 24 h treatment. *, ** and *** p values < 0.05, < 0.005 and < 0.001 compared to untreated control and ### p values < 0.001 compared to ER 5.0 μ M and ER 10.0 μ M treated samples, respectively (Figure 7C). *, ** and *** p values < 0.05, and < 0.005 compared to untreated control and ##, ### p values < 0.005 and < 0.001 compared to ER 5.0 μ M and ER 10.0 μ M treated samples, respectively (Figure 7G). Student's t -test was used for statistical analysis using Graph Pad Prism (GraphPad Software, Inc., La Jolla, CA, USA).

3.8. Erastin Decreases FSP1 and NQO1 Expressions in MCF-7 Cells

To further elucidate the mechanism underlying the differential enhancement of ER cytotoxicity by FSP1 inhibitors in MCF-7 cells, we performed RT-PCR analyses to examine the effects of ER on the expression of *FSP1*, *NQO1*, and other antioxidant genes in MCF-7 and MXR cells. ER significantly suppressed the expression of both *FSP1* and *NQO1* in MCF-7 cells, whereas no significant changes were observed in MXR cells (Figure 6B). In addition, ER markedly modulated the expression of multiple antioxidant response genes in MCF-7 cells, including *NRF2*, *GSR*, *SOD1*, and *SOD2* (Figure 6B). Although ER reduced *NRF2* expression in MXR cells, this effect was significantly weaker than that observed in MCF-7 cells, and ER had no measurable impact on *GSR*, *SOD1*, or *SOD2* expression in MXR cells.

Basal gene expression levels of *GPX4*, *SCL7A11*, *FSP1* and *NQO1* were also compared which showed significant differences between MCF-7 and MXR cells (Figure 6C). *GPX4* and *FSP1* expression levels were comparable between MCF-7 and MXR cells; however, MXR cells exhibited significantly reduced expression of both *SLC7A11* and *NQO1*, indicating that differences in ferroptosis sensitivity may arise from impaired cystine uptake and redox cofactor regeneration rather than from altered expression of core ferroptosis suppressor proteins.

4. Discussion

While significant achievements have been made in the treatment of breast cancer, it is still a leading cause of cancer death in women worldwide, accounting for 23% of cancer diagnoses and 14% of cancer deaths each year [1,3,34]. In breast cancer, drug resistance is responsible for up to 90% of deaths and multidrug resistance (MDR) hinders the efficacy of chemotherapeutic drugs, often leading to relapse and metastasis [35]. A major cause of treatment failure is due to the development of therapy resistance and new therapeutic agents are urgently needed. Recently, ferroptosis has attracted significant attention in the treatment of human tumors, including breast cancers, as ferroptosis-inducing agents can sensitize resistant tumor cells to chemotherapeutic agents. Studies have shown that ferroptosis inducers such as ER can reverse drug resistance and sensitize tumor cells to various chemotherapeutic agents in multiple ABC transporter-expressing cell lines. Zhou et al. [18] reported that docetaxel, an ABCB1 substrate, is highly synergistic with ER in an ABCB1-expressing ovarian cancer cell line. Erastin significantly increased intracellular docetaxel accumulation by inhibiting the drug-efflux activity of ABCB1 without altering its expression, suggesting that the combination of ER and docetaxel may represent an effective strategy for treating chemo-resistant ovarian cancer. Our previous studies [19,20] also demonstrated strong synergy between ER and doxorubicin (Adriamycin) in an ABCB1-overexpressing ovarian cancer cell line. In addition, ER markedly enhanced the cytotoxicity of topotecan in an ABCG2-overexpressing breast cancer cell line. In all cases, the reversal of drug resistance was associated with ER-mediated inhibition of transporter function, leading to increased intracellular drug accumulation.

Consistent with these findings, Chen et al. [36] showed that ER synergized with docetaxel in docetaxel-resistant prostate cancer cells, overexpressing the ABCB1 protein. Erastin inhibited ABCB1 activity without affecting its protein expression or subcellular localization, indicating that ER reverses docetaxel resistance by suppressing the function of this multidrug-resistance transporter.

Furthermore, ER has been reported to sensitize ovarian cancer cells to cisplatin [37], while PRLX939, an ER analog, synergized with cisplatin in non-small-cell lung cancer cells [38]. RSL3 has also been shown to act synergistically with several anticancer drugs and with radiotherapy [39]. Sorafenib, a tyrosine kinase inhibitor and ferroptosis inducer,

enhances sensitivity to cisplatin [40] and doxorubicin [41]. Similarly, sulfasalazine, a system xCT inhibitor and potent ferroptosis inducer, has demonstrated synergy with cisplatin [42] and doxorubicin [43] in bladder and breast cancer cells, respectively. Collectively, these studies highlight the potential of ferroptosis inducers as promising agents for overcoming chemotherapy resistance in clinical settings.

Our studies show that both ER and RSL3 are markedly more cytotoxic to MCF-7/MXR cells than the parent MCF-7 breast cancer cells. The mechanisms of ER resistance to tumor cells remain understudied and there is an urgent need to understand reasons for this in breast and other cancers for better treatment options. In this study, we sought to understand both the mechanism (s) of ER-dependent cell death and how resistance to ferroptosis-inducing agents develops in breast cancer cells. Studies showed that while MCF-7 cells are resistant to ER, RSL3, a direct inhibitor of GPX4, sensitized both MCF-7 and MXR breast tumor cells to ER. However, RSL3 was less effective in MCF-7 cells than MXR cells, indicating that GPX4 is responsible, in part, for the decreased toxicity of ER in MCF-7 cells. MCF-7 cells have been shown to have high GSH and GPX4 activity [44]. Additionally, we found that ER did not induce MDA formation in MCF-7 cells while MXR cells were highly sensitive to ER, generating significant amounts of MDA. Presence of RSL3 again significantly enhanced MDA formation in MCF-7 without affecting MXR cells, indicating that GPX4 is involved in decreased MDA formation in MCF-7 cells. Cytotoxicity of ER was inhibited by FES (inhibitor of lipid radicals) and DFO (an iron chelator) in both cell lines, indicating ferroptotic cell death by ER. Furthermore, NAC, an inhibitor of ROS also significantly inhibited the cytotoxicity of ER and RSL3 in both cell lines, indicating ROS-mediated cell death. Formation of ROS was confirmed in both cells.

We found that ER significantly induced the expression of *HMOX1*, a biomarker of oxidative stress, in both cell lines. However, ER-dependent induction of *HMOX1* was more pronounced in the MXR cells than in the MCF-7 cells, consistent with the increased ROS production we observed in MXR cells. However, effects of ER on *GPX4* and *SLC7A11*, two genes responsible for either use or import of cellular GSH respectively, were markedly different in these cell lines. Expression of *GPX4* and *SLC7A11* were significantly decreased by ER in MXR cells while expression of these genes was increased in MCF-7 cells. This suggests that the GSH-GPX4 pathway may be more active in MXR cells than in MCF-7 cells, potentially contributing to increased cell death. Still, that MCF-7 cells showed minimal lipid peroxidation and markedly reduced cytotoxicity in response to ER suggests that additional ferroptosis-inhibiting pathways may be involved.

To investigate additional pathways responsible for ER-resistance in MCF-7 cells, we utilized inhibitors of FSP1, a protein that confers resistance to both ferroptosis and apoptosis in tumor cells [17,28,30,45–47]. Two different inhibitors of FSP1, FSEN1 and iFSP1, were utilized to examine their effects on ER-induced cell death in these cell lines. Minimally cytotoxic doses of these inhibitors were significantly effective in enhancing ER-induced cytotoxicity in MCF-7 cells without modulating ER cytotoxicity in MXR cells. This differential enhancement of ER cytotoxicity in MCF-7 cells suggest that FSP1 plays a significant role in protecting MCF-7 cells from ferroptotic death, resulting in decreased cytotoxicity of ER. These conclusions are further highlighted by our finding that there are significant differences in expression levels of ferroptosis-related genes, *SLC7A11* and *NQO1* between MCF-7 and MXR cells despite comparable *GPX4* and *FSP1* expression. MCF-7 cells exhibited significantly higher levels of *SLC7A11* and *NQO1*, whereas MXR cells showed marked downregulation of both genes. Since *SLC7A11* plays critical roles in cystine uptake and glutathione synthesis and *NQO1* in coenzyme Q redox cycling, these findings indicate that MXR cells possess an impaired upstream redox and metabolic capacity to support ferroptosis defense. This molecular context provides a mechanistic explanation for our

drug response data, in which combined inhibition of system xCT (ER) and FSP1 produced strong synergistic cytotoxicity in MCF-7 cells but not in MXR cells. In MCF-7 cells, elevated *SLC7A11* and *NQO1* sustain parallel GPX4- and FSP1-dependent protective pathways, rendering dual pathway blockade highly effective. In contrast, reduced *SLC7A11* and *NQO1* expression in MXR cells limit glutathione availability and CoQ redox buffering upstream of GPX4 and FSP1, thereby diminishing the added benefit of FSP1 inhibition.

These results highlight a previously uncharacterized mechanistic divergence in ferroptosis regulation between MCF-7 and MXR breast cancer cells. MXR cells exhibit classical GPX4-dependent ferroptosis sensitivity, whereas MCF-7 cells are protected by a robust FSP1-driven defense system, rendering them less responsive to ER alone. This mechanistic distinction has important implications for designing targeted therapies aimed at overcoming ferroptosis resistance in breast cancer. Unfortunately, FSP1 inhibitors such as iFSP1 and FSEN1 are not in the clinic due to poor solubility, limited potency, and unfavorable chemical scaffolds that restrict further medicinal chemistry optimization into viable therapeutic agents. Moreover, FSP1 is expressed in both normal and tumor tissues, posing a significant challenge for achieving cancer-selective inhibition without inducing toxicity in healthy cells. Nevertheless, these compounds serve as valuable experimental tools for elucidating the role of FSP1 in regulating ferroptosis in preclinical models.

5. Conclusions

This study demonstrates that parental MCF-7 breast cancer cells and their MXR derivative exhibit fundamentally different mechanisms governing their sensitivity to ferroptosis induction. MCF-7 resistance to ER arises primarily from activation of the FSP1–CoQ10–NADPH pathway and upregulation of the GSH–GPX4 antioxidant system, which together suppress lipid peroxidation and ferroptotic death. In contrast, MXR cells rely heavily on the xCT–GSH–GPX4 axis, making them highly susceptible to ER-induced ferroptosis. Our findings identify FSP1 as a critical regulator of ferroptosis resistance in MCF-7 cells and suggest that co-targeting GPX4 and FSP1 may provide a powerful strategy to sensitize resistant breast cancer cells to ferroptosis-inducing agents. These insights improve our understanding of ferroptosis regulation in breast cancer and support further investigation into combination therapies involving ER, RSL3, and FSP1 inhibitors as potential approaches to overcome drug resistance.

Author Contributions: B.B.S.: Methodology, data analysis and editing. C.M.: Methodology. E.J.T.: Data analysis and editing. B.K.S.: Conceptualization and experimental design, writing—original draft, data curation, investigation, methodology and editing. All authors have read and agreed to the published version of the manuscript.

Funding: The authors declare that financial support was received for authorship and publication for this article. This research was supported by the intramural research program (Grant number ZIA E505013922 and CARCI-HEI#) of the National Institute of Environmental Health Sciences, NIH. Statements contained herein do not necessarily represent the statements, opinions or conclusions of NIEHS, NIH, or the US government.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are contained within the manuscript and are available upon request.

Acknowledgments: The authors thank B. Alex Merrick and Sidney Bony for their critical evaluation of the manuscript.

Conflicts of Interest: The authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

Abbreviations

Erastin, ER; Ras-selected ligand 3, RSL3; Mitoxantrone-selected MCF-7 Resistance cell line, MCF-7/MXR (MXR), Glutamate/cystine antiporter, xCT, Glutathione Peroxidase 4, GPX4; Ferroptosis Suppressor Protein 1, FSP1; Reactive Oxygen Radical, ROS; Breast Cancer Resistance Protein, BCRP; NAC, N-acetyl cysteine; Deferoxamine, DFO; Ferrostatin-1, FES; Malondialdehyde, MDA; Ferroptosis Sensitizer 1, FSEN1; Ferroptosis inhibitor, iFSP1; NADPH Quinone Oxidoreductase 1, NQO1; Nuclear factor erythroid 2-related factor-2, Nrf2; Glutathione reductase, GSR.

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J. Clin.* **2021**, *71*, 209–249. [\[CrossRef\]](#) [\[PubMed\]](#)
2. Kinnel, B.; Singh, S.K.; Oprea-Ilie, G.; Singh, R. Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer. *Cancers* **2023**, *15*, 1320. [\[CrossRef\]](#) [\[PubMed\]](#)
3. Wu, G.Y.; Xiao, M.Z.; Hao, W.C.; Yang, Z.S.; Liu, X.R.; Xu, D.S.; Peng, Z.X.; Zhang, L.Y. Drug resistance in breast cancer: Mechanisms and strategies for management. *Drug Resist. Updates* **2025**, *83*, 101288. [\[CrossRef\]](#)
4. Qi, X.; Wan, Z.; Jiang, B.; Ouyang, Y.; Feng, W.; Zhu, H.; Tan, Y.; He, R.; Xie, L.; Li, Y. Inducing ferroptosis has the potential to overcome therapy resistance in breast cancer. *Front. Immunol.* **2022**, *13*, 1038225. [\[CrossRef\]](#) [\[PubMed\]](#)
5. Yang, J.; Jia, Z.; Zhang, J.; Pan, X.; Wei, Y.; Ma, S.; Yang, N.; Liu, Z.; Shen, Q. Metabolic Intervention Nanoparticles for Triple-Negative Breast Cancer Therapy via Overcoming FSP1-Mediated Ferroptosis Resistance. *Adv. Healthc. Mater.* **2022**, *11*, e2102799. [\[CrossRef\]](#)
6. Dixon, S.J.; Lemberg, K.M.; Lamprecht, M.R.; Skouta, R.; Zaitsev, E.M.; Gleason, C.E.; Patel, D.N.; Bauer, A.J.; Cantley, A.M.; Yang, W.S.; et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. *Cell* **2012**, *149*, 1060–1072. [\[CrossRef\]](#)
7. Chen, X.; Li, J.; Kang, R.; Klionsky, D.J.; Tang, D. Ferroptosis: Machinery and regulation. *Autophagy* **2021**, *17*, 2054–2081. [\[CrossRef\]](#) [\[PubMed\]](#)
8. Li, J.; Cao, F.; Yin, H.L.; Huang, Z.J.; Lin, Z.T.; Mao, N.; Sun, B.; Wang, G. Ferroptosis: Past, present and future. *Cell Death Dis.* **2020**, *11*, 88. [\[CrossRef\]](#)
9. Singh, M.; Arora, H.L.; Naik, R.; Joshi, S.; Sonawane, K.; Sharma, N.K.; Sinha, B.K. Ferroptosis in Cancer: Mechanism and Therapeutic Potential. *Int. J. Mol. Sci.* **2025**, *26*, 3852. [\[CrossRef\]](#)
10. Stockwell, B.R.; Friedmann Angeli, J.P.; Bayir, H.; Bush, A.I.; Conrad, M.; Dixon, S.J.; Fulda, S.; Gascon, S.; Hatzios, S.K.; Kagan, V.E.; et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. *Cell* **2017**, *171*, 273–285. [\[CrossRef\]](#) [\[PubMed\]](#)
11. Halliwell, B. Commentary for “Oxygen free radicals and iron in relation to biology and medicine: Some problems and concepts”. *Arch. Biochem. Biophys.* **2022**, *718*, 109151. [\[CrossRef\]](#)
12. Sinha, B.K. Ferroptosis in Toxicology: Present and Future. *Int. J. Mol. Sci.* **2025**, *26*, 6658. [\[CrossRef\]](#)
13. Dixon, S.J.; Patel, D.N.; Welsch, M.; Skouta, R.; Lee, E.D.; Hayano, M.; Thomas, A.G.; Gleason, C.E.; Tatonetti, N.P.; Slusher, B.S.; et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. *eLife* **2014**, *3*, e02523. [\[CrossRef\]](#) [\[PubMed\]](#)
14. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. *Chem. Biol.* **2008**, *15*, 234–245. [\[CrossRef\]](#)
15. Gaschler, M.M.; Stockwell, B.R. Lipid peroxidation in cell death. *Biochem. Biophys. Res. Commun.* **2017**, *482*, 419–425. [\[CrossRef\]](#)
16. Doll, S.; Freitas, F.P.; Shah, R.; Aldrovandi, M.; da Silva, M.C.; Ingold, I.; Goya Grocin, A.; Xavier da Silva, T.N.; Panzilius, E.; Scheel, C.H.; et al. FSP1 is a glutathione-independent ferroptosis suppressor. *Nature* **2019**, *575*, 693–698. [\[CrossRef\]](#)
17. Bersuker, K.; Hendricks, J.M.; Li, Z.; Magtanong, L.; Ford, B.; Tang, P.H.; Roberts, M.A.; Tong, B.; Maimone, T.J.; Zoncu, R.; et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. *Nature* **2019**, *575*, 688–692. [\[CrossRef\]](#)
18. Zhou, H.H.; Chen, X.; Cai, L.Y.; Nan, X.W.; Chen, J.H.; Chen, X.X.; Yang, Y.; Xing, Z.H.; Wei, M.N.; Li, Y.; et al. Erastin Reverses ABCB1-Mediated Docetaxel Resistance in Ovarian Cancer. *Front. Oncol.* **2019**, *9*, 1398. [\[CrossRef\]](#)
19. Brown, S.M.; Sinha, B.K.; Cannon, R.E. A Role for iNOS in Erastin Mediated Reduction of P-Glycoprotein Transport Activity. *Cancers* **2024**, *16*, 1733. [\[CrossRef\]](#) [\[PubMed\]](#)

20. Perera, L.; Brown, S.M.; Silver, B.B.; Tokar, E.J.; Sinha, B.K. Ferroptosis Inducers Erastin and RSL3 Enhance Adriamycin and Topotecan Sensitivity in ABCB1/ABCG2-Expressing Tumor Cells. *Int. J. Mol. Sci.* **2025**, *26*, 635. [\[CrossRef\]](#) [\[PubMed\]](#)
21. Nakagawa, M.; Schneider, E.; Dixon, K.H.; Horton, J.; Kelley, K.; Morrow, C.; Cowan, K.H. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. *Cancer Res.* **1992**, *52*, 6175–6181.
22. Mimnaugh, E.G.; Trush, M.A.; Gram, T.E. Stimulation by adriamycin of rat heart and liver microsomal NADPH-dependent lipid peroxidation. *Biochem. Pharmacol.* **1981**, *30*, 2797–2804. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Sinha, B.K.; Tokar, E.J.; Bushel, P.R. Elucidation of Mechanisms of Topotecan-Induced Cell Death in Human Breast MCF-7 Cancer Cells by Gene Expression Analysis. *Front. Genet.* **2020**, *11*, 775. [\[CrossRef\]](#)
24. Kubenova, L.; Haberland, J.; Dvorak, P.; Samaj, J.; Ovecka, M. Spatiotemporal distribution of reactive oxygen species production, delivery, and use in Arabidopsis root hairs. *Plant Physiol.* **2023**, *193*, 2337–2360. [\[CrossRef\]](#)
25. Almujaally, H.; Abuharfeil, N.; Sharaireh, A. Novel Exosomal miRNA Expression in Irradiated Human Keratinocytes. *Int. J. Mol. Sci.* **2024**, *25*, 12477. [\[CrossRef\]](#)
26. Park, E.; Chung, S.W. ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation. *Cell Death Dis.* **2019**, *10*, 822. [\[CrossRef\]](#) [\[PubMed\]](#)
27. Sinha, B.K.; Murphy, C.; Brown, S.M.; Silver, B.B.; Tokar, E.J.; Bortner, C.D. Mechanisms of Cell Death Induced by Erastin in Human Ovarian Tumor Cells. *Int. J. Mol. Sci.* **2024**, *25*, 8666. [\[CrossRef\]](#) [\[PubMed\]](#)
28. Li, W.; Liang, L.; Liu, S.; Yi, H.; Zhou, Y. FSP1: A key regulator of ferroptosis. *Trends Mol. Med.* **2023**, *29*, 753–764. [\[CrossRef\]](#)
29. Chen, H.; Wang, C.; Liu, Z.; He, X.; Tang, W.; He, L.; Feng, Y.; Liu, D.; Yin, Y.; Li, T. Ferroptosis and Its Multifaceted Role in Cancer: Mechanisms and Therapeutic Approach. *Antioxidants* **2022**, *11*, 1504. [\[CrossRef\]](#) [\[PubMed\]](#)
30. Koppula, P.; Lei, G.; Zhang, Y.; Yan, Y.; Mao, C.; Kondiparthi, L.; Shi, J.; Liu, X.; Horbath, A.; Das, M.; et al. A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers. *Nat. Commun.* **2022**, *13*, 2206. [\[CrossRef\]](#)
31. Lee, J.; Roh, J.L. Unleashing Ferroptosis in Human Cancers: Targeting Ferroptosis Suppressor Protein 1 for Overcoming Therapy Resistance. *Antioxidants* **2023**, *12*, 1218. [\[CrossRef\]](#)
32. Hendricks, J.M.; Doubravsky, C.E.; Wehri, E.; Li, Z.; Roberts, M.A.; Deol, K.K.; Lange, M.; Lasheras-Otero, I.; Momper, J.D.; Dixon, S.J.; et al. Identification of structurally diverse FSP1 inhibitors that sensitize cancer cells to ferroptosis. *Cell Chem. Biol.* **2023**, *30*, 1090–1103.e7. [\[CrossRef\]](#)
33. Zhang, S.; Megarioti, A.H.; Hendricks, J.M.; Zhou, J.; Sun, Q.; Jia, D.; Olzmann, J.A. Cocystal structure reveals the mechanism of FSP1 inhibition by FSEN1. *Proc. Natl. Acad. Sci. USA* **2025**, *122*, e2505197122. [\[CrossRef\]](#) [\[PubMed\]](#)
34. Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **2024**, *74*, 229–263. [\[CrossRef\]](#)
35. Khan, M.M.; Yalamarty, S.S.K.; Rajmalani, B.A.; Filipczak, N.; Torchilin, V.P. Recent strategies to overcome breast cancer resistance. *Crit. Rev. Oncol. Hematol.* **2024**, *197*, 104351. [\[CrossRef\]](#) [\[PubMed\]](#)
36. Chen, F.; Wu, S.; Kuang, N.; Zeng, Y.; Li, M.; Xu, C. ABCB1-mediated docetaxel resistance reversed by erastin in prostate cancer. *FEBS J.* **2024**, *291*, 3249–3266. [\[CrossRef\]](#)
37. Cheng, Q.; Bao, L.; Li, M.; Chang, K.; Yi, X. Erastin synergizes with cisplatin via ferroptosis to inhibit ovarian cancer growth in vitro and in vivo. *J. Obstet. Gynaecol. Res.* **2021**, *47*, 2481–2491. [\[CrossRef\]](#)
38. Liang, Z.; Zhao, W.; Li, X.; Wang, L.; Meng, L.; Yu, R. Cisplatin synergizes with PRLX93936 to induce ferroptosis in non-small cell lung cancer cells. *Biochem. Biophys. Res. Commun.* **2021**, *569*, 79–85. [\[CrossRef\]](#)
39. Nie, Z.; Chen, M.; Gao, Y.; Huang, D.; Cao, H.; Peng, Y.; Guo, N.; Wang, F.; Zhang, S. Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges. *Front. Pharmacol.* **2022**, *13*, 879317. [\[CrossRef\]](#)
40. Wang, Y.; Wang, L. Effect of Combined Sorafenib/Cisplatin Treatment on the Autophagy and Proliferation of Hepatocellular Carcinoma hepG2 Cells in Vitro. *Asian Pac. J. Cancer Prev.* **2020**, *21*, 2853–2857. [\[CrossRef\]](#) [\[PubMed\]](#)
41. Yang, Y.T.; Yuzbasiyan-Gurkan, V. Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines. *Int. J. Mol. Sci.* **2022**, *23*, 9345. [\[CrossRef\]](#) [\[PubMed\]](#)
42. Ogihara, K.; Kikuchi, E.; Okazaki, S.; Hagiwara, M.; Takeda, T.; Matsumoto, K.; Kosaka, T.; Mikami, S.; Saya, H.; Oya, M. Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer. *Cancer Sci.* **2019**, *110*, 1431–1441. [\[CrossRef\]](#) [\[PubMed\]](#)
43. Narang, V.S.; Pauletti, G.M.; Gout, P.W.; Buckley, D.J.; Buckley, A.R. Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: Enhancement of growth-inhibitory activity of Doxorubicin. *Chemotherapy* **2007**, *53*, 210–217. [\[CrossRef\]](#)
44. Theodossiou, T.A.; Olsen, C.E.; Jonsson, M.; Kubin, A.; Hothersall, J.S.; Berg, K. The diverse roles of glutathione-associated cell resistance against hypericin photodynamic therapy. *Redox Biol.* **2017**, *12*, 191–197. [\[CrossRef\]](#)
45. Tahsin, T.; McPhail, D.K.; Champion, J.D.; Alzahrani, M.A.M.; Hilditch, M.L.; Faris-Orr, A.; Calver, B.L.; Cronin, J.G.; Mareque-Rivas, J.C.; Sexton, D.W.; et al. Targeting NRF2 and FSP1 to Overcome Ferroptosis Resistance in TSC2-Deficient and Cancer Cells. *Cancers* **2025**, *17*, 2714. [\[CrossRef\]](#) [\[PubMed\]](#)

46. Zhang, Q.; Li, N.; Deng, L.; Jiang, X.; Zhang, Y.; Lee, L.T.O.; Zhang, H. ACSL1-induced ferroptosis and platinum resistance in ovarian cancer by increasing FSP1 N-myristylation and stability. *Cell Death Discov.* **2023**, *9*, 83. [[CrossRef](#)]
47. Dai, Q.; Wei, X.; Zhao, J.; Zhang, D.; Luo, Y.; Yang, Y.; Xiang, Y.; Liu, X. Inhibition of FSP1: A new strategy for the treatment of tumors (Review). *Oncol. Rep.* **2024**, *52*, 105. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.